Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE262.804.7 (+1.82 % )
PREV CLOSE (Rs.) 258.10
OPEN PRICE (Rs.) 260.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 118344
TODAY'S LOW / HIGH (Rs.)258.90 263.55
52 WK LOW / HIGH (Rs.)230 359.18
NSE262.90 4.75 (+1.84 % )
PREV CLOSE(Rs.) 258.15
OPEN PRICE (Rs.) 259.95
BID PRICE (QTY) 262.90 (12 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3398831
TODAY'S LOW / HIGH(Rs.) 259.00 263.80
52 WK LOW / HIGH (Rs.)230 359

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.19
TTM EPS (Rs.) 4.11
P/E Ratio 64.01
Book Value (Rs.) 61.29
Face Value (Rs.) 5
MCap (Rs. in Mn) 315360.00
Price/Earning (TTM) 49.29
Price/Sales (TTM) 10.93
Price/Book (MRQ) 4.29
PAT Margin (%) 17.08
ROCE (%) 7.89
Incorporation Year : 1978

Management Info :

Kiran Mazumdar-Shaw - Chairman Kiran Mazumdar-Shaw - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 080 2808 2808

Website : www.biocon.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
08Jul07-08-2019$USFDA completes inspection at Biocon’s Insulins facilities in Malaysia USFDA completes inspection a

US Food and Drug Administration (USFDA) has completed inspection at Biocon’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia. A per-approval inspection by USFDA was carried out from June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

US Food and Drug Administration (USFDA) has completed inspectio..
08Jul07-08-2019$Biocon inches up on the bourses Biocon inches up on the bour

Biocon is currently trading at Rs. 240.60, up by 0.85 points or 0.35% from its previous closing of Rs. 239.75 on the BSE.

The scrip opened at Rs. 233.95 and has touched a high and low of Rs. 243.35 and Rs. 230.00 respectively. So far 181500 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 359.18 on 26-Sep-2018 and a 52 week low of Rs. 230.00 on 08-Jul-2019.

Last one week high and low of the scrip stood at Rs. 256.70 and Rs. 230.00 respectively. The current market cap of the company is Rs. 28806.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.43% and 17.89% respectively.

US Food and Drug Administration (USFDA) has completed inspection at Biocon’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia. A per-approval inspection by USFDA was carried out from June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 240.60, up by 0.85 points or..
08Jul07-08-2019$Biocon informs about company updates Biocon informs about company

Biocon has informed about Pre -Approval US FDA Inspection Conducted at Biocon's lnsulins Facilities in Malaysia. 

The above information is a part of company’s filings submitted to BSE.

Biocon has informed about Pre -Approval US FDA Inspection Condu..
19Jun06-19-2019$Biocon shines on getting nod to sell BFI Business to Biocon Biologics Biocon shines on getting nod

Biocon is currently trading at Rs. 251.55, up by 8.45 points or 3.48% from its previous closing of Rs. 243.10 on the BSE.

The scrip opened at Rs. 244.05 and has touched a high and low of Rs. 252.50 and Rs. 242.80 respectively. So far 164795 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 359.18 on 26-Sep-2018 and a 52 week low of Rs. 238.90 on 18-Jun-2019.

Last one week high and low of the scrip stood at Rs. 259.00 and Rs. 238.90 respectively. The current market cap of the company is Rs. 30012.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.28% and 17.05% respectively.

Biocon has received approval for sale of Branded Formulations India (BFI) Business of the Company on a 'going concern' basis to Biocon Biologics India (BBIL), a wholly owned subsidiary. The transfer of BFI business on slump sale basis will lead to consolidation of marketing and manufacturing activities relating to BFI business under a single entity with common leadership and achieve synergies / value accretion for the group. The Board of Directors of the Company at its meeting held on June 17, 2019 has approved the same.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 251.55, up by 8.45 points or..
18Jun06-18-2019$Biocon to sell BFI Business to Biocon Biologics Biocon to sell BFI Business

Biocon has received approval for sale of Branded Formulations India (BFI) Business of the Company on a 'going concern' basis to Biocon Biologics India (BBIL), a wholly owned subsidiary. The transfer of BFI business on slump sale basis will lead to consolidation of marketing and manufacturing activities relating to BFI business under a single entity with common leadership and achieve synergies / value accretion for the group. The Board of Directors of the Company at its meeting held on June 17, 2019 has approved the same.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon has received approval for sale of Branded Formulations I..
Financials More
Rs. in Millions
QTR Mar 19 ANNUAL 19
Net Profit7054927
Gross Profit 743 5521
Operating Profit 11245031
Net Sales 763928847
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 4904.00 (4.13%)
M.Cap ( in Cr)
8140.34
Sanofi India (BSE)
 5886.70 (0.77%)
M.Cap ( in Cr)
13557.44
Themis Medicare (BSE)
 251.30 (19.98%)
M.Cap ( in Cr)
230.72
Ajanta Pharma (BSE)
 928.70 (2.61%)
M.Cap ( in Cr)
8103.35
Piramal Enterprises (BSE)
 2058.00 (1.04%)
M.Cap ( in Cr)
40922.62
Shareholding Pattern More
PROMOTERS 60.67 %
MUTUAL FUNDS/UTI 2.89 %
NON-INSTITUTION 17.89 %
FI/BANKS/INSURANCE 1.21 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes